Return to homepagePandemic Pact

Tumaini Study - Pivotal Phase 2/3 Bundibugyo vaccine trial

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications

Grant number: NCT07842107

Grant search

Key facts

  • Disease

    Ebola

  • Start & end year

    N/A

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Research Location

    Congo (DRC)

  • Lead Research Institution

    Institut National de Recherche Biomédicale (INRB)

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

This pivotal Phase 2/3 clinical trial will evaluate the safety, immunogenicity and efficacy of vaccine candidates against Bundibugyo virus (BDBV), including Ervebo which is currently licensed for use to prevent Ebola virus (EBOV). The trial will support the Government-led response to the ongoing outbreak in the Democratic Republic of the Congo (DRC).